BioArctic

BioArctic Long-term Debt

The Long-Term Debt of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 28.35 M SEK. In the previous year, Long-Term Debt was 41.08 M SEK — a change of -30.99% (lower).

Long-term Debt

28.35 MSEK

YoY

-30.99%

Last updated:

Long-Term Debt of BioArctic is 2025 28.35 M SEK. Long-Term Debt of BioArctic was 2024 41.08 M SEK. It decreases by -30.99% lower compared to the previous year.

The BioArctic Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
0.00 SEK
Jan 1, 2019
20.93 M SEK
Jan 1, 2020
13.63 M SEK
Jan 1, 2021
7.79 M SEK
Jan 1, 2022
1.18 M SEK
Jan 1, 2023
2.15 M SEK
Jan 1, 2024
41.08 M SEK
Jan 1, 2025
28.35 M SEK
The BioArctic Long-term Debt history
YEARLong-term DebtYoY
28.35 MSEK-30.99%
41.08 MSEK+1,808.88%
2.15 MSEK+82.06%
1.18 MSEK-84.82%
7.79 MSEK-42.87%
13.63 MSEK-34.88%
20.93 MSEK—
0.00SEK—
0.00SEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Long-Term Debt of BioArctic is 28.35 M SEK in 2025.

Long-Term Debt of BioArctic changed from 41.08 M SEK to 28.35 M SEK, representing a -30.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt BioArctic since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioArctic

All Key Metrics — BioArctic